Patient-reported outcomes assessment in cancer trials: taking stock, moving forward.

Patient-reported outcomes assessment in cancer trials: taking stock, moving forward. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Patient-reported outcomes assessment in cancer trials: taking stock, moving forward. Abstract Text:

Joseph Lipscomb,Bryce B Reeve,Steven B Clauser,Jeffrey S Abrams,Deborah Watkins Bruner,Laurie B Burke,Andrea M Denicoff,Patricia A Ganz,Kathleen Gondek,Lori M Minasian,Ann M O'Mara,Dennis A Revicki,Edwin P Rock,Julia H Rowland,Maria Sgambati,Edward L Trimble,

To evaluate and improve the use of cancer trial end points that reflect the patient's own perspective, the National Cancer Institute organized an international conference, Patient-Reported Outcomes Assessment in Cancer Trials (PROACT), in 2006. The 13 preceding articles in this special issue of the Journal were commissioned in preparation for or in response to the PROACT conference, which was cosponsored by the American Cancer Society. Drawing from these articles and also commentary from the conference itself, this concluding report takes stock of what has been learned to date about the successes and challenges in patient-reported outcome (PRO) assessment in phase III, phase II, and symptom management trials in cancer and identifies ways to improve the scientific soundness, feasibility, and policy relevance of PROs in trials. Building on this synthesis of lessons learned, this article discusses specific administrative policies and management procedures to improve PRO data collection, analysis, and dissemination of findings; opportunities afforded by recent methodologic and technologic advances in PRO data collection and analysis to enhance the scientific soundness and cost efficiency of PRO use in trials; and the importance of better understanding the usefulness of PRO data to the full spectrum of cancer decision makers, including patients and families, health providers, public and private payers, regulatory agencies, and standards-setting organizations.

Patient-reported outcomes assessment in cancer trials: taking stock, moving forward. Publishing Authors By Initials

J Lipscomb,BB Reeve,SB Clauser,JS Abrams,DW Bruner,LB Burke,AM Denicoff,PA Ganz,K Gondek,LM Minasian,AM O'Mara,DA Revicki,EP Rock,JH Rowland,M Sgambati,EL Trimble,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Patient-reported outcomes assessment in cancer trials: taking stock, moving forward. Journal Published:

PUBLICATION TYPE: Review

Journal: Journal of clinical oncology : official journal of

VOLUME: 25

Page Numbers: 5133-40

Journal Abbreviation:

ISSN: 1527-7755

DAY: 10

MONTH: Nov

YEAR: 2007

Patient-reported outcomes assessment in cancer trials: taking stock, moving forward. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 8309333

Patient-reported outcomes assessment in cancer trials: taking stock, moving forward. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Patient-reported outcomes assessment in cancer trials: taking stock, moving forward. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Patient-reported outcomes assessment in cancer trials: taking stock, moving forward.

AFFILIATION: Emory University, Atlanta, GA 30322, USA. jlipsco@sph.emory.edu

Country: United States

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: J Clin Oncol

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Patient-reported outcomes assessment in cancer trials: taking stock, moving forward Related Publications

• Are patients with somatization disorder highly suggestible?
• Behavioral correlates of posteromedial parietal cortex hypometabolism in a family with idiopathic basal ganglia calcifications.
• Body image and the temporal lobes.
• Comparison of efficacy of pheromone dispensing technologies for controlling the grape berry moth (Lepidoptera: Tortricidae) by mating disruption.
• Correspondence between self-ratings and key-workers' ratings of depression in adults with mild learning disabilities.
• Demographic, clinical, and treatment trends among women diagnosed with vulvar cancer in the United States.
• Embracing alternative perspectives.
• Fenofibrate and pioglitazone improve endothelial function and reduce arterial stiffness in obese glucose tolerant men.
• Funding patient-reported outcomes in cancer clinical trials.
• Harold Guyon Trimble; 1896-1957.
• Health-related quality of life and symptom management research sponsored by the National Cancer Institute.
• Infusion-aspiration control.
• Interictal psychoses of epilepsy.
• Mammalian SEPT2 is required for scaffolding nonmuscle myosin II and its kinases.
• Neurobiologic perspectives.
• Neurobiologic perspectives.
• Numbering fingers.
• Patient-reported outcomes assessment in cancer trials: taking stock, moving forward.
• Patterns of care for cervical cancer patients treated in the U.S. military health care system.
• Promotion of bicycle helmet use among schoolchildren: a randomized clinical trial.
• Sept12 is a component of the mammalian sperm tail annulus.
• The changing concept in pneumonia.
• The coblentz society newsletter.
• The contemporary relevance of neuropsychiatry.
• The dopaminergic projection system, Basal forebrain macrosystems, and conditioned stimuli.
• The lesson of encephalitis lethargica.
• The septin CDCrel-1 is dispensable for normal development and neurotransmitter release.
• The utilization of collapse therapy.
• The ventral striatum as an interface between the limbic and motor systems.
• Transcranial magnetic stimulation.